Logo

Illumina Stock Slides 5.53 Percent on Analyst Downgrade

Jun 10, 2005

NEW YORK, June 10 (GenomeWeb News) - Shares in Illumina were down 5.53 percent, or $.67, at $11.45 in mid-afternoon trading after an investment bank downgraded the company's stock.

 

Robert W. Baird downgraded the stock to "Neutral" from "Outperform."

 

Also today, investment bank Leerink Swann began covering Illumina with an "Outperform" rating.

Breaking News
The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.